Document:

exv10w3

 

Exhibit 10.3

SECOND AMENDMENT TO 

OEM AGREEMENT

     This Second Amendment to OEM Agreement, (“Amendment”) is made and entered into as of December 31,
2004 (“Amendment Date”), by and between Akorn-Strides, LLC, a Delaware limited liability company,
having a principal place of business at 2500 Millbrook Drive, Buffalo Grove, Illinois 60089-4694,
United States of America (“A-S”), and Strides Arcolab Limited, a company organized under the laws
of India having a principal place of business at Strides House, Bilekahalli, Bannerghatta Road,
Bangalore 560 076, India (“Strides”), (each a “Party” and collectively the “Parties”).

RECITALS

     A. A-S and Strides are parties to that certain OEM Agreement dated September 22, 2004
(“agreement”);

     B. A-S and Strides desire to amend the Agreement to clarify the treatment of the Registration
Payment made by A-S, pursuant to the terms and conditions of this Amendment.

NOW, THEREFORE, in consideration of the mutual promises contained herein and other valuable
consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:

1. Definitions. All capitalized terms used herein shall have the same meanings set forth
in the Agreement, unless otherwise defined in this Amendment.

2. Funding of Registration Costs. The following text in added to the Agreement as a new
Section 2.3.3:

	 	2.3.3	 	The Parties acknowledge that the Registration Payment made by
A-S pursuant to Section 2.3.1 and the additional Registration Payment that A-S
may make pursuant to its own discretion pursuant to Section 2.3.2 represent
consideration for the preparation by Strides of the ANDAs set forth in the ANDA
Schedule.

3. Counterparts. This Amendment may be executed in several counterparts that together
shall be originals and constitute one and the same instrument.

4. Effect. Except as modified above, the Agreement shall remain in full force and effect
in accordance with its specific terms.

Page 1

 

 

     IN WITNESS WHEREOF, the parties hereto, through their duly authorized officers, have executed this
Amendment as of the Amendment Date.

	 	 	 	 	 	 	 	 
	Akorn-Strides, LLC

	 	Strides Arcolab Limited
	 
	 
	By:
	 	/s/ Arthur S. Przybyl 	 	By:	 	/s/ Arun Kumar 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Name:
	 	Arthur S. Przybyl 	 	Name:
	 	Arun Kumar 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Its:

	 	Member Manager 
	 	Its:
	 	Executive Vice Chairman & MD 
	 

	 	 
	 	 	 	 
	

	 	 	 	 	 	 
	

	 	 	 	 	 	 
	

	 	 	 	 	 	 

Page 2exv10w4

 

Exhibit 10.4

*Confidential Treatment Requested Under

17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

THIRD AMENDMENT TO 

OEM AGREEMENT

This Third
Amendment to OEM Agreement, (“Amendment”) is made and
entered into as of October 26,
2005 (“Amendment Date”), by and between Akorn-Strides, LLC, a Delaware limited liability company,
having a principal place of business at 2500 Millbrook Drive, Buffalo Grove, Illinois 60089-4694,
United States of America (“A-S”), and Strides Arcolab Limited, a company organized under the laws
of India having a principal place of business at Strides House, Bilekahalli, Bannerghatta Road,
Bangalore 560 076, India (“Strides”), (each a “Party” and collectively the “Parties”).

RECITALS

     A. A-S and Strides are parties to that certain OEM Agreement dated September 22, 2004
(“Agreement”) and desire to amend the Agreement to revise the ANDA Schedule, pursuant to the terms
and conditions of this Amendment.

NOW, THEREFORE, in consideration of the mutual promises contained herein and other valuable
consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:

1.    Definitions. All capitalized terms used herein shall have the same meanings set forth
in the Agreement, unless otherwise defined in this Amendment.

2.    Modification of ANDA Schedule. Exhibit B of the Agreement is deleted in its entirety
and replaced with Exhibit B attached hereto and fully incorporated herein (“New ANDA Schedule”).
The Parties also hereby acknowledge that the schedule, attached hereto as Attachment 1 was a
previously adopted, although unsigned schedule originally intended to supercede the original
Exhibit B attached to the Agreement but which itself is being superceded pursuant to this Amendment
with the New ANDA Schedule.

3.    Counterparts. This Amendment may be executed in several counterparts that together
shall be originals and constitute one and the same instrument.

4.    Effect. Except as modified above, the Agreement shall remain in full force and effect
in accordance with its specific terms.

IN WITNESS WHEREOF, the parties hereto, through their duly authorized officers, have executed this
Amendment as of the Amendment Date.

	 	 	 	 	 	 	 	 
	Akorn-Strides, LLC

	 	Strides Arcolab Limited
	 
	 
	By:

	 	/s/ Arthur S. Przybyl 
	 	By:
	 	/s/ Arun Kumar 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Name:

	 	Arthur S. Przybyl 
	 	Name:
	 	Arun Kumar 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Its:

	 	Member Manager 
	 	Its:
	 	Executive Vice Chairman & MD 
	 

	 	 
	 	 	 	 
	

	 	 	 	 	 	 
	

	 	 	 	 	 	 
	

	 	 	 	 	 	 

Page 1

 

*Confidential Treatment Requested Under
17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

EXHIBIT B

ANDA SCHEDULE

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	Dossier	 	API Cost	 	Upgrade	 	Total Cost of	 	Status of
	Sl. No.	 	Product Name	 	STRENGTH	 	Cost	 	over 10K	 	contbn	 	Dossier	 	Dossier
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	2
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Semi-

Exclusive**
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	4
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	5
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	6
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	7
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	8
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	9
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	10
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	11
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	12
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	13
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	14
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	15
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	NOTE:-PRODUCTS CAN BE DROPPED OR SUBSTITUTED BASED ON JOINT DECISION BY AKORN/STRIDES JV

** Notwithstanding the terms of this Agreement to the contrary, the Parties acknowledge that
[...*...] only may be sold by Strides in the Territory in the Exclusive Market to one other entity
only in addition to A-S.

* CONFIDENTIAL TREATMENT REQUESTED — This language has been omitted and filed
separately with the Securities and Exchange Commission.

 

*Confidential Treatment Requested under
17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

ATTACHMENT 1

SUPERCEDED INTERMEDIATE SCHEDULE

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Dossier	 	API Cost	 	Upgrade	 	Total Cost of	 	Status of
	Sl. No.	 	Product Name	 	STRENGTH	 	Cost	 	over 10K	 	contbn	 	Dossier	 	Dossier
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	2
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Semi-Exclusive**
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	4
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	5
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	6
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	7
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	8
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	9
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	10
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	11
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	12
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	13
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	14
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	15
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	16
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	17
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	18
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	19
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	20
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	Exclusive
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	[...*...]
	 	[...*...]
	 	[...*...]
	 	[...*...]	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	NOTE:-PRODUCTS CAN BE DROPPED OR SUBSTITUTED BASED ON JOINT DECISION BY AKORN/STRIDES JV

* CONFIDENTIAL TREATMENT REQUESTED — This language has been omitted and filed
separately with the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]